Light Chain, which draws on decades of experience in immunology and antibody-based therapies gained as Novimmune, is now seeking partners to take forward candidates identified by Light Chain ...

By these arrangements, each of the two arms of the antibody includes one light chain and one heavy chain, with the variable regions at the tips of the Y arms defining antigen specificity.

The following is a summary of “Diagnostic Utility of Kappa Free Light Chain Index in Adults With Inaugural Optic Neuritis,” ...

is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. Its platform includes common light chain-focused antibody discovery ...

CEPI, the Coalition for Epidemic Preparedness Innovations, yesterday announced a $43.5 million deal with pharmaceutical giant AstraZeneca to advance the development of a novel antibody that could ...

Paradox is focused on the development of treatment for immunoglobulin light chain amyloidosis (AL amyloidosis ... platform and bringing much-needed antibody therapies to market.” ...